USA - New York Stock Exchange - NYSE:SYK - US8636671013 - Common Stock
The current stock price of SYK is 372.29 USD. In the past month the price increased by 0.73%. In the past year, price decreased by -5.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.76 | 223.72B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.69 | 205.85B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.22 | 149.60B | ||
| IDXX | IDEXX LABORATORIES INC | 59.95 | 60.48B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.58B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.75 | 50.34B | ||
| RMD | RESMED INC | 25.76 | 37.22B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.57 | 36.73B | ||
| DXCM | DEXCOM INC | 33.62 | 24.52B | ||
| PODD | INSULET CORP | 71.51 | 22.99B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.06 | 19.32B | ||
| HOLX | HOLOGIC INC | 17.52 | 16.64B |
Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. The company is headquartered in Portage, Michigan and currently employs 53,000 full-time employees. The firm offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The firm also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
STRYKER CORP
1941 Stryker Way
Portage MICHIGAN 49002 US
CEO: Kevin A. Lobo
Employees: 53000
Phone: 12693852600
Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. The company is headquartered in Portage, Michigan and currently employs 53,000 full-time employees. The firm offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The firm also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
The current stock price of SYK is 372.29 USD. The price decreased by -0.74% in the last trading session.
STRYKER CORP (SYK) has a dividend yield of 0.93%. The yearly dividend amount is currently 3.2.
SYK has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
STRYKER CORP (SYK) currently has 53000 employees.
STRYKER CORP (SYK) has a market capitalization of 142.33B USD. This makes SYK a Large Cap stock.
You can find the ownership structure of STRYKER CORP (SYK) on the Ownership tab.
ChartMill assigns a technical rating of 3 / 10 to SYK. When comparing the yearly performance of all stocks, SYK is a bad performer in the overall market: 67.77% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to SYK. SYK has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months SYK reported a non-GAAP Earnings per Share(EPS) of 13.17. The EPS increased by 13.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.07% | ||
| ROA | 6.25% | ||
| ROE | 13.51% | ||
| Debt/Equity | 0.68 |
37 analysts have analysed SYK and the average price target is 438.19 USD. This implies a price increase of 17.7% is expected in the next year compared to the current price of 372.29.
For the next year, analysts expect an EPS growth of 11.17% and a revenue growth 10.86% for SYK